Journal of Pharmaceutical Care & Health Systems
Open Access

New emerging drugs for treatment of dyslipidemia: Review on clinical studies

Pharmaceutical Summit and Expo

October 08-10, 2015 New Delhi, India

Syed Azeemuddin Razvi

Deccan School of Pharmacy, India

Posters-Accepted Abstracts: J Pharma Care Health Sys

Abstract :

Statins being very effective and safe in numerous randomized clinical trials became the first-line treatment against atherogenic dyslipidemia. However, even with optimal statin treatment, 60% to 80% of residual cardiovas�?¬cular risk still exists. The patients with Familial Hypercholesterolemia (FH) which results in extremely high level of Low Density Lipopro�?¬tein Cholesterol (LDL-C) level and the patients who are intolerant or unresponsive to statins are the other hurdles of statin treat�?¬ment. Recently, new classes of lipid-lowering drugs have been developed: â�?¢ The pro-protein convertase subtilisin/kexintype 9 (PCSK9) inhibitor increases the expression of LDL receptor in hepatocytes by enhancing LDL receptor recycling. It recently showed promising results of significant LDL-C lower�?¬ing in FH patients from the long-term phase III trials. â�?¢ The microsomal triglyceride transport protein (MTP) inhibitor and antisense oligonucleotide against apolipoprotein B (ApoB) reduce the ApoB containing lipoprotein by blocking the hepatic very low density lipoprotein (VLDL) synthesis pathway. â�?¢ The apolipoprotein A1 (ApoA1) mimetics pursuing the beneficial effect of high density lipoprotein cholesterol and can reverse the course of atherosclerosis. However it needs more validation in humans. â�?¢ 2, 3-diaryl-substituted indole-based Cyclooxygenase-2 (COX-2) inhibitors (2,3-diaryl-indole coxibs) are potent antiinflammatory agents and also show the ability to scavenge Reactive Oxygen Species (ROS). Therefore act as potent inhibitors of oxidative modification of Low-Density Lipoprotein (LDL), which is considered a key factor in atherogenesis. We would discuss the benefits and concerns of these new lipid-lowering drugs anticipating additional benefits beyond statin treatment.

Biography :

Syed Azeemuddin Razvi is a PharmD student at Deccan School of Pharmacy, affiliated to Jawaharlal Nehru Technological University.

Email: azeemrazvi92@gmail.com